Objective To analyze the clinical effect of rosuvastatin on blood lipid and CRP in patients with acute coronary syndrome (ACS). Methods From Jan. 2012 to Jan. 2015, a total of 90 patients with ACS were selected in our hospital and randomly divided into observation group (45 cases) and control group (45 cases). Patients in the control group were given atorvastatin, the other patients in the observation group were given rosuvastatin, and both of them were treated for 28 days. After treatment, the blood lipid levels including TG, TC, HDL, LDL and hs-CRP were compared, clinical effects and adverse reactions were recorded. Results Both the two group of TG, TC, HDL, LDL and hs-CRP were significantly lower than that before treatment (P<0.05). After treatment, the TG, LDL and hs-CRP levels of the observation group were (1.40±0.17)mmol/L,(2.60±0.49)mmol/L and (6.46±2.01)mg/L which were significantly lower than those of the control group (P<0.05), and the success rates of LDL and hs-CRP were 82.22% and 88.89% which were significantly higher than those of the control group (P<0.05), the total effective rate of the observation group was 91.11% which was significantly higher than that of the control group 75.56%, the adverse reactions rate of the observation group was 6.67% which was significantly lower than that of the control group 24.44%(P<0.05). Conclusion Compared with atorvastatin, rosuvastatin can effectively improve blood lipid and CRP in patients with ACS and greatly reduce the incidence of adverse reactions.